Merck Looks Ahead To Phase III-Rich Period As Keytruda Winds Down
The drugmaker announced its fourth quarter and full-year results for 2025, highlighting significant revenue opportunities ahead across indications.
Scrip - February 3, 2026

Pfizer Is Bullish On Obesity As It Gets Back In The Game
Management said it sees big potential for obesity drugs as cash-pay medications in the global market, while reporting Q4 financial results.
Scrip - February 3, 2026

Analysts Question Competitiveness Of Pfizer’s Monthly GLP-1 In Obesity
Long-acting GLP-1 agonist obtained in the Metsera deal beats placebo in 28-week weight loss in Phase IIb, but analysts note the data come in below Zepbound’s 28-week efficacy.
Scrip - February 3, 2026

Multiple Injuries Associated With Early Alert For Certain Abiomed Impella Heart Pumps
The US FDA says Abiomed has reported 22 serious injuries linked to an issue with some of its temporary heart pumps that provide support to patients with acute right heart failure.
Medtech Insight - February 3, 2026

BCI Developer INBRAIN Races Ahead With Bidirectional Chip, Merck Commercialization Letter, Trial
INBRAIN unveiled a bidirectional "rice-sized" BCI chip partnership, Merck commercialization progress and new speech-decoding trial in France as it advances its graphene-based cortical interface toward commercialization, pending regulatory clearance.
Medtech Insight - February 3, 2026

Stryker Elevates Spencer Stiles To President, COO As Scale And Tariffs Shape Outlook
Stryker’s leadership transition and operational execution were in focus during the company’s latest earnings call, as executives outlined changes to senior management, progress on margins amid tariff pressures, and confidence in sustained organic growth.
Medtech Insight - February 3, 2026

OTC Brands Aren’t Window Dressing, They Are The Door To Responsible Self-Care
Umbrella branding in OTC medicines supports responsible self?care by helping consumers navigate choices, build trust and confidence, and access reliable health information, countering regulators’ long?standing focus on risks rather than benefits, says PAGB CEO Michelle Riddalls.
HBW Insight - February 3, 2026

Kiwifruit Supplement Falls Short In UK Health Claim Bid
UK rejects proposed health claim from AFT Pharma, “Green kiwifruit powder contributes to the maintenance of normal defecation.”
HBW Insight - February 3, 2026

Can Roche Overcome BTK Inhibitor Doubts To Be First In Multiple Sclerosis?
Safety concerns look to have finished off Sanofi’s competitor, tolebrutinib, leaving Roche’s fenebrutinib as the possible first-in-class BTK inhibitor for multiple sclerosis - but much still depends on a final Phase III readout.
Scrip - February 3, 2026

EU Not The Land Of Plenty For Acadia After Rett Therapy Snub
The CHMP has delivered a negative trend vote on the US firm's filing for Daybue.
Scrip - February 3, 2026

Stock Watch: Roche Rescued By The Dividend
Roche’s decision to increase the dividend served to bolster its stock performance after revenue growth from a basket of patent-expired products exceeded key growth drivers like Vabysmo and full-year 2026 revenue guidance underwhelmed.
Scrip - February 3, 2026

France Gives Go-Ahead For Private-Equity Buyout Of Biogaran – But With Strings
BC Partners has completed its acquisition from Servier of French generics giant Biogaran after the French government allowed the private-equity takeover on condition that BPI France take a minority stake. Meanwhile, former Biogaran CEO Erick Roche has returned to the role after a long stint at Teva.
Generics Bulletin - February 3, 2026

Samsung Bioepis Settles Global Launches For Its Eylea Biosimilar
Just a few days after Alvotech announced global settlements for its Eylea rival, Samsung Bioepis has followed up with its own agreements with the originators.
Generics Bulletin - February 3, 2026

Novo’s CagriSema Outshines Semaglutide In Phase III Diabetes Study
The experimental GLP-1/amylin combination shows promise in type 2 diabetes, but competition will be fierce with some massive launches expected in 2026.
Scrip - February 3, 2026

Teva Dishes On Plans To File Olanzapine LAI In Europe
Teva is lining up Europe as the next regulatory market for its long-acting injectable olanzapine, following its US filing late last year, as the company looks to build a global schizophrenia franchise.
Generics Bulletin - February 3, 2026

Cell And Gene Therapy Enters ‘Disciplined Growth Cycle’ As Commercial Momentum Builds
Cell and gene therapy is shifting into a new phase, as maturing commercial launches, rising big pharma participation and regulatory momentum replace hype and skepticism.
In Vivo - February 3, 2026

India To Scale Biopharma, Trial Network, Big Pharma Gets Import Duty Cuts
India’s budget backs plans to scale production of biologics and biosimilars, shore up its clinical trials network and strengthen the regulatory framework. Customs duty exemptions given to several big pharma therapies, including those of Novartis and Takeda.
Scrip - February 3, 2026